Format

Send to

Choose Destination
Indian Dermatol Online J. 2019 Jan-Feb;10(1):50-53. doi: 10.4103/idoj.IDOJ_135_18.

Plasma Cell Myeloma Masquerading as Scleromyxedema.

Author information

1
Department of General Medicine, St. John's Medical College, Bengaluru, Karnataka, India.

Abstract

Scleromyxedema is a rare progressive cutaneous mucinosis of unknown etiology with equal prevalence in both men and women. It is usually associated with monoclonal gammopathy in most of the cases. Various treatment modalities have been tried for scleromyxedema including steroids, intravenous immunoglobulin (IVIg), autologous hematopoietic stem cell transplantation, and melphalan, but none has proved to be fully effective. This paper reports a case of scelromyxedema in a patient who was found to have multiple myeloma on further evaluation. The patient was treated with six cycles of bortezomib, thalidomide, and dexamethasone, following which he had complete resolution of his skin lesions. While recent case reports have mentioned treatment of patients of scleromyxedema with varying combinations of IVIg, thalidomide, bortezomib, and dexamethasone, we describe a patient who has been successfully treated with a combination of bortezomib, thalidomide, and dexamethasone with complete resolution of all skin lesions.

KEYWORDS:

Bortezomib; dexamethasone; plasma cell myeloma; scleromyxedema; thalidomide

Supplemental Content

Full text links

Icon for Medknow Publications and Media Pvt Ltd Icon for PubMed Central
Loading ...
Support Center